Doctor Robert Willan was the first to accurately describe the different types of psoriasis in the early 1800s. In the early 1960s, experts found that psoriasis was an autoimmune disorder, and modern treatment began in the mid-1900s.
In 1809, the English doctor Robert Willan was the first to develop an accurate description of the different types of psoriasis. While doctors learned more about the condition over the years, a pivotal finding emerged in 1963, when E. J. Van Scott found that psoriasis was an autoimmune disorder.
Modern treatment for this condition became available in the mid-1900s, and doctors still use these treatments today. Options include ultraviolet light and medications to reduce inflammation and suppress the immune system.
This article discusses the history and discovery of psoriasis and how treatment has changed.
According to the Psoriasis and Psoriatic Arthritis Alliance, people were aware of psoriasis as early as ancient Greece. Hippocrates wrote some of the first descriptions of skin conditions. However, he classified psoriasis in the same category as leprosy (Hansens disease).
People continued to classify psoriasis in the same category as Hansens disease for several centuries, and as a result, people with psoriasis often experienced stigma and were outcasts from society.
During the Renaissance period, several people wrote books further categorizing skin conditions. Two Italian authors, Girolamo Mercuriale and Bernardino Ramazzini, began to describe different skin conditions, including psoriasis, in their books De Morbius Cutaneis and De Morbis Artificum.
In 1809, the English doctor Robert Willan also categorized skin conditions. He was the first person to provide a description of different types of psoriasis, and he wrote about the progression of the condition.
While Robert Willan was the first person to investigate psoriasis as a separate condition, he still used the term lepra vulgaris, which contributed to people associating psoriasis with leprosy.
In the 1800s, the Austrian physician Ferdinand von Hebra was the first to use modern research techniques to study skin conditions. He also removed lepra from the description of psoriasis.
During this century, French doctors discovered the connection between psoriasis and a form of arthritis called psoriatic arthritis.
Other medical professionals of the time continued to make discoveries that led to later research subcategorizing psoriasis. For example, Australian dermatologist William J. Munro discovered mico-abscesses in the top layer of the skin in people with this condition. Later research would find that these abscesses are part of psoriasis vulgaris, a common form of this condition.
Heinrich Kbner made an important discovery during the 19th century. He found that people with psoriasis may also develop psoriatic lesions in previously unaffected areas that have experienced trauma, such as a cut, burn, or bruise. Doctors still use the Kbner phenomenon as a diagnostic tool today.
The 20th century saw various advancements in the classification of psoriasis and its symptoms.
In 1910, Leo von Zumbusch was the first to describe pustular psoriasis, a rare type of psoriasis that causes pustules, blisters, fever, and fatigue.
In 1926, Dr. Woronoff discovered that people with psoriasis may have a pale ring of skin around healing lesions. This halo, or Woronoff ring, is another diagnostic tool that medical professionals use. The appearance of a Woronoff ring may be a sign that psoriasis lesions are healing.
In 1963, E. J. Van Scott found that people with psoriasis have a rapid turnover of cells, which is a marker of an autoimmune condition. This discovery that psoriasis is an autoimmune condition affected the way doctors treated this condition.
A 1973 paper by John M. Moll and Verna Wright linked psoriasis to psoriatic arthritis. This was one of the first research papers to distinguish psoriatic arthritis from rheumatoid arthritis.
The understanding that psoriasis is an autoinflammatory condition rather than a skin disease has led to advances in treatment. In auto-inflammatory conditions, the immune system attacks healthy tissue and cells in the body.
Within the last decade, discoveries in genetics and molecular science have led to a greater understanding of how psoriasis affects people. Researchers now know that the cause is a complex interaction between immunological, environmental, cellular, and genetic factors.
One of the earliest treatments for psoriasis was coal tar. Medical professionals may still recommend using coal tar as a first-line treatment in cases of mild plaque psoriasis. And they may recommend it in combination with other medications for cases of moderate or severe plaque psoriasis.
In the 1920s, William Goeckerman developed Goeckerman therapy, which combined UVB light with coal tar to treat psoriasis. Doctors still use this treatment today for moderate or severe psoriasis.
Throughout the 1900s, experts created several new treatments, such as:
Biologic drugs are the most recent development in the treatment of psoriasis. These drugs interrupt the immune process of the condition, which can help ease its symptoms. A 2018 study reports that biologics are highly effective and lead to dramatic improvements in 8090% of people with psoriasis.
Healthcare professionals may also prescribe topical and oral retinoids, such as acitretin (Soriatane). Experts are also investigating the effectiveness of Janus kinase (JAK) inhibitors, which healthcare professionals already use in the treatment of rheumatoid arthritis and psoriatic arthritis.
People have been aware of psoriasis for centuries and often grouped this condition with leprosy (Hansens disease). Over time, experts began to recategorize this condition and learn more about how it affects the body, eventually discovering it is an autoimmune condition.
Similarly, treatment has evolved over time to become more effective. There are now several options that a doctor may recommend, many of which were first discovered in the 1900s.
Excerpt from:
The discovery and history of psoriasis: What to know - Medical News Today
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]
- Woman, 29, Slams Bullies Who 'Giggle And Whisper' At Her Unsightly Psoriasis Sores And Scabs, Leaving Her Depressed And 'Struggling To Walk' -... - August 15th, 2022 [August 15th, 2022]
- Serum Calprotectin Levels Linked to Subclinical Carotid Atherosclerosis in Patients With Psoriatic Arthritis - Rheumatology Network - August 15th, 2022 [August 15th, 2022]
- Why skin is the forgotten frontier of the beauty acceptance movement - Sydney Morning Herald - August 8th, 2022 [August 8th, 2022]
- Lilly's Taltz (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience - PR Newswire - August 8th, 2022 [August 8th, 2022]
- Cleveland Clinic: Can the sun be beneficial for some skin conditions? - WFMJ - August 8th, 2022 [August 8th, 2022]
- Almirall S A : and Happify Health go live with digital therapeutics support for psoriasis patients - Marketscreener.com - August 8th, 2022 [August 8th, 2022]
- UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis -... - August 8th, 2022 [August 8th, 2022]